Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC

▸ TREATMENT

A U.S. healthcare payer analysis evaluated nivolumab plus ipilimumab versus pembrolizumab and chemotherapy as first-line treatment for the 4-5% of metastatic colorectal cancers that are microsatellite instability-high or mismatch repair deficient. (Advances in Therapy)